Key result
Thrombophilia testing led to appropriate anticoagulation decisions in only 6% of 3,550 patients, demonstrating limited clinical usefulness despite high-risk cases having more thromboembolic events.
Why the study?
Thrombophilia testing utility has remained controversial due to limited data on its influence on treatment decisions.
Does thrombophilia testing influence treatment decisions and predict subsequent thromboembolic or pregnancy-related events in patients referred for consultation?
Population
3550 unselected patients referred for thrombophilia consultation at Bern University Hospital
Comparison
Thrombophilia vs without thrombophilia
Design
Single-center retrospective cohort study
Follow-up
Median 49 months (range, 1−183 months)
Authors
Loading...
Thrombophilia testing rarely influenced anticoagulation decisions appropriately; leaves open its prognostic role in high-risk cases for prospective validation.
Cohort (n=3,550)
No
Does thrombophilia testing influence treatment decisions and predict subsequent thromboembolic or pregnancy-related events in patients referred for consultation?
Thrombophilia testing has limited utility in clinical decision-making for anticoagulation, though high-risk thrombophilia remains a predictor for subsequent venous thromboembolism and pregnancy-related morbidity.
Vrotniakaite-Bajerciene et al. (2022) conducted a cohort in Thrombophilia (n=3,550). Thrombophilia testing vs. No thrombophilia was evaluated on Influence on treatment decisions. Thrombophilia testing led to appropriate anticoagulation decisions in only 6% of 3,550 patients, demonstrating limited clinical usefulness despite high-risk cases having more thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: